Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model

This study developed a physiologically based pharmacokinetic (PBPK) model in intraabdominally infected rats and extrapolated it to humans to predict the levofloxacin pharmacokinetics and penetration into tissues. Twelve male rats with intraabdominal infections induced by Escherichia coli received a single dose of 50 mg/kg body weight of levofloxacin. Blood plasma was collected at 5, 10, 20, 30, 60, 120, 240, 480 and 1440 min after injection, respectively. A PBPK model was developed in rats and extrapolated to humans using GastroPlus software. The predictions were assessed by comparing predictions and observations. In the plasma concentration-versus-time profile of levofloxacin in rats, Cmax was 23.570 μg/ml at 5 min after intravenous injection, and t1/2 was 2.38 h. The plasma concentration and kinetics in humans were predicted and validated by the observed data. Levofloxacin penetrated and accumulated with high concentrations in the heart, liver, kidney, spleen, muscle and skin tissues in humans. The predicted tissue-to-plasma concentration ratios in abdominal viscera were between 1.9 and 2.3. When rat plasma concentrations were known, extrapolation of a PBPK model was a method to predict the drug pharmacokinetics and penetration in humans. Levofloxacin had good penetration into the liver, kidney and spleen as well as other tissues in humans. This pathological model extrapolation may provide a reference for the study of antiinfective PK/PD. In our study, levofloxacin penetrated well into abdominal organs. Also ADR monitoring should be implemented when using levofloxacin.

[1]  G. Eliopoulos,et al.  In vitro activities in new oxazolidinone antimicrobial agents against enterococci , 1996, Antimicrobial agents and chemotherapy.

[2]  R. Mannhold,et al.  Calculation of molecular lipophilicity: state of the art and comparison of methods on more than 96000 compounds , 2009, Journal of pharmaceutical sciences.

[3]  F. Zhang,et al.  Simultaneous determination of isoniazid, rifampicin, levofloxacin in mouse tissues and plasma by high performance liquid chromatography-tandem mass spectrometry. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[4]  M. Rowland,et al.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.

[5]  M. Graham,et al.  Pharmacokinetics and Pharmacodynamics of Intravenous Levofloxacin at 750 Milligrams and Various Doses of Metronidazole in Healthy Adult Subjects , 2004, Antimicrobial Agents and Chemotherapy.

[6]  M. Kays,et al.  Comparative In Vitro Activity and Pharmacodynamics of Five Fluoroquinolones Against Clinical Isolates of Streptococcus pneumoniae , 2000, Pharmacotherapy.

[7]  L. A. Fenu,et al.  The Prediction of Drug Metabolism, Tissue Distribution, and Bioavailability of 50 Structurally Diverse Compounds in Rat Using Mechanism-Based Absorption, Distribution, and Metabolism Prediction Tools , 2007, Drug Metabolism and Disposition.

[8]  L. Preheim,et al.  Effect of Ethanol on Fluoroquinolone Efficacy in a Rat Model of Pneumococcal Pneumonia , 2006, Antimicrobial Agents and Chemotherapy.

[9]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[10]  M. Yasuhara,et al.  Effect of levofloxacin on serum glucose concentration in rats. , 2006, European journal of pharmacology.

[11]  Stefan Willmann,et al.  Defining the Role of Macrophages in Local Moxifloxacin Tissue Concentrations using Biopsy Data and Whole-Body Physiologically Based Pharmacokinetic Modelling , 2009, Clinical pharmacokinetics.

[12]  D J Triggle,et al.  Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. , 2001, Molecular pharmacology.

[13]  Igor V. Tetko,et al.  Calculation of molecular lipophilicity: state of the art and comparison of methods on more than 96000 compounds , 2009 .

[14]  M. Landoni,et al.  Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats. , 2004, Journal of veterinary pharmacology and therapeutics.

[15]  A. Camm,et al.  Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers. , 2010, British journal of clinical pharmacology.

[16]  Rui Chen,et al.  Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling , 2012, Acta Pharmacologica Sinica.

[17]  H. Geiss,et al.  Tissue and serum concentrations of levofloxacin 500 mg administered intravenously or orally for antibiotic prophylaxis in biliary surgery. , 2003, The Journal of antimicrobial chemotherapy.

[18]  Gordon M. Crippen,et al.  Predicting pKa , 2009, J. Chem. Inf. Model..

[19]  M. Schilling,et al.  Liver tissue concentrations of levofloxacin after single intravenous administration of 500 mg for antibiotic prophylaxis in liver surgery. , 2006, International journal of antimicrobial agents.

[20]  Y. Gomita,et al.  Interaction between Levofloxacin and Vancomycin in Rats – Study of Serum and Organ Levels , 1998, Chemotherapy.

[21]  H. Gerner,et al.  Tissue and serum concentrations of levofloxacin in orthopaedic patients. , 2001, International journal of antimicrobial agents.

[22]  C. Kohlsdorfer,et al.  Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats. , 1999, The Journal of antimicrobial chemotherapy.

[23]  T. Tsai,et al.  Pharmacokinetic study of levofloxacin in rat blood and bile by microdialysis and high-performance liquid chromatography. , 2002, Journal of chromatography. A.

[24]  H. Sasabe,et al.  Carrier-mediated hepatic uptake of quinolone antibiotics in the rat. , 1997, The Journal of pharmacology and experimental therapeutics.

[25]  D. Barends,et al.  Rediguieri CF, Porta V, Nunes DSG, Nunes TM, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2011. Biowaiver monographs for immediate‐release solid oral dosage forms: Metronidazole. J Pharm Sci 100:1618–1627. , 2011 .

[26]  Andrew Campbell.  Development of PBPK model of molinate and molinate sulfoxide in rats and humans. , 2009, Regulatory toxicology and pharmacology : RTP.

[27]  Yue He,et al.  Tamsulosin alters levofloxacin pharmacokinetics in prostates derived from rats with acute bacterial prostatitis. , 2013, Asian journal of andrology.

[28]  C. Destache,et al.  Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. , 2001, The Journal of antimicrobial chemotherapy.

[29]  Yuichi Sugiyama,et al.  Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[30]  D. Fish,et al.  The Clinical Pharmacokinetics of Levofloxacin , 1997, Clinical pharmacokinetics.

[31]  C. Cox,et al.  A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. , 1998, Urology.

[32]  D. Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: levofloxacin. , 2011, Journal of pharmaceutical sciences.

[33]  Gordon M. Crippen,et al.  Predicting p K a . , 2009 .

[34]  S. Finegold,et al.  In Vitro Activity of Levofloxacin against a Selected Group of Anaerobic Bacteria Isolated from Skin and Soft Tissue Infections , 1998, Antimicrobial Agents and Chemotherapy.

[35]  S. Masuda,et al.  Distribution Characteristics of Levofloxacin and Grepafloxacin in Rat Kidney , 1999, Pharmaceutical Research.

[36]  H. Lode,et al.  Levofloxacin Pharmacokinetics and Serum Bactericidal Activities against Five Enterobacterial Species , 2000, Antimicrobial Agents and Chemotherapy.

[37]  K. Mori,et al.  Mechanism of histamine release induced by levofloxacin, a fluoroquinolone antibacterial agent. , 2000, European journal of pharmacology.

[38]  Hanwen Sun,et al.  Characterization of Interactions Between Fluoroquinolones and Human Serum Albumin by CE–Frontal Analysis , 2008 .

[39]  Thierry Lavé,et al.  Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. , 2009, Molecular pharmaceutics.

[40]  H. Eichler,et al.  Drug Distribution , 1998, Clinical pharmacokinetics.